Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mild to fulminant necrotizing vaso-occlusive retinitis associated with a high incidence of retinal detachment and poor vision outcome.
Biomarker and diagnostic research for acute retinal necrosis syndrome has been reported in the published literature.
No clinical trials have been registered for acute retinal necrosis syndrome.
126 publications have been identified in PubMed for acute retinal necrosis syndrome. Research spans Case Report / Case Series (50%), Epidemiology / Natural History (15%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 63 | 50% |
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 11:35 PM UTC
Common questions about acute retinal necrosis syndrome
Disease patterns and progression
19 |
15% |
Research summaries | 17 | 13% |
Clinical study results | 10 | 8% |
Laboratory research | 10 | 8% |
Testing and diagnosis research | 3 | 2% |
Other research | 2 | 2% |
New treatment approaches | 2 | 2% |
Zou Y (2026). [PMID: 42252088](https://pubmed.ncbi.nlm.nih.gov/42252088/). *Ophthalmol Retina*. [Epidemiology / Natural History]
Minor M (2026). [PMID: 32491711](https://pubmed.ncbi.nlm.nih.gov/32491711/). *Unknown Journal*. [Review / Meta-Analysis]
Tripathy K (2026). [PMID: 29262034](https://pubmed.ncbi.nlm.nih.gov/29262034/). *Unknown Journal*. [Review / Meta-Analysis]
Azeem S (2026). [PMID: 42044482](https://pubmed.ncbi.nlm.nih.gov/42044482/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Banaji SH (2026). [PMID: 41969835](https://pubmed.ncbi.nlm.nih.gov/41969835/). *Case Rep Ophthalmol*. [Case Report / Case Series]
Gu W (2026). [PMID: 41754410](https://pubmed.ncbi.nlm.nih.gov/41754410/). *Pathogens (Basel, Switzerland)*. [Gene Therapy / Novel Therapeutics]
Werner M (2026). [PMID: 41159916](https://pubmed.ncbi.nlm.nih.gov/41159916/). *The Journal of experimental medicine*. [Basic Science / Preclinical]
Priyadarshini S (2026). [PMID: 42200735](https://pubmed.ncbi.nlm.nih.gov/42200735/). *Indian J Ophthalmol*. [Epidemiology / Natural History]
Takeda A (2026). [PMID: 41366138](https://pubmed.ncbi.nlm.nih.gov/41366138/). *Japanese journal of ophthalmology*. [Review / Meta-Analysis]
Magaki S (2026). [PMID: 41491635](https://pubmed.ncbi.nlm.nih.gov/41491635/). *Brain pathology (Zurich, Switzerland)*. [Case Report / Case Series]
AI-curated news mentioning acute retinal necrosis syndrome
Updated May 27, 2026
A new report discusses the challenges in managing macular edema following acute retinal necrosis. This condition complicates treatment strategies and highlights the need for further research in effective management approaches.
A recent study published in PubMed examines the clinical features and outcomes of acute retinal necrosis presenting with exudative retinal detachment. The findings provide insights into the disease's progression and potential treatment strategies.
A recent study published in PubMed discusses the occurrence of acute retinal detachment following the implantation of Ozurdex in a nonvitrectomized eye. This finding highlights potential risks associated with the use of this drug in specific patient populations.